Table 3.
Involvement of Lymphocyte Subsets in Rejection of B16-BL6 through Cotreatment with Anti–CTLA-4 and BL6/GM Vaccine
| Depletion | B16-BL6 tumor take | Remarks |
|---|---|---|
| CD4 | 2/10 | Depigmentation (4/8 survivors) |
| CD8 | 9/10 | — |
| CD4 plus CD8 | 5/5 | — |
| NK1.1 | 8/10 | Multiple tumors developed at injection site, no depigmentation |
| Control mouse IgG | 5/10 | Depigmentation (3/5 survivors) |
| Control rat IgG | 4/10 | Depigmentation (4/6 survivors) |
| No depletion | 5/10 | Depigmentation (3/5 survivors) |
| No depletion, no treatment | 10/10 | — |
Depletion of lymphocyte subsets was achieved by injecting depleting antibodies GK1.5 (anti-CD4), 2.43 (CD8), PK136 (NK1.1), or control antibodies at days −8, −7, −6, and every 7 (GK1.5) to 10 d thereafter. Depletion was checked at day −1. Results are compiled from two experiments.